Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response
To explore the relationship between metabolic uptake of the 18F-ALF-NOTA-PRGD2 (18F-RGD) tracer on positron emission tomography/computerized tomography (PET/CT) and the antiangiogenic effect of apatinib in patients with solid malignancies.
Materials and patients
Patients with measurable lesions scheduled for second- or third-line single-agent therapy with apatinib were eligible for this prospective clinical trial. All patients underwent 18F-RGD PET/CT examination before the start of treatment. Standardized uptake values (SUVs) of contoured tumor lesions were computed and compared using independent sample t-tests or the Mann–Whitney U test. Receiver-operating characteristic (ROC) curve analysis was used to determine accuracy in predicting response. Survival curves were compared using the Kaplan–Meier method.
Of 38 patients who consented to study participation, 25 patients with 42 measurable lesions met the criteria for inclusion in this response assessment analysis. The median follow-up time was 3 months (range, 1–10 months), and the median progression-free survival (PFS) was 3 months (95% confidence interval, 1.04–4.96). The SUVpeak and SUVmean were significantly higher in responding tumors than in non-responding tumors (4.98 ± 2.34 vs 3.59 ± 1.44, p = 0.048; 3.71 ± 1.15 vs 2.95 ± 0.49, P = 0.036). SUVmax did not differ between responding tumors and non-responding tumors (6.58 ± 3.33 vs 4.74 ± 1.83, P = 0.078). An exploratory ROC curve analysis indicated that SUVmean [area under the ROC curve (AUC) = 0.700] was a better parameter than SUVpeak (AUC = 0.689) for predicting response. Using a threshold value of 3.82, high SUVmean at baseline was associated with improved PFS (5.0 vs. 3.4 months, log-rank P = 0.036).
18F-RGD uptake on PET/CT imaging pretreatment may predict the response to antiangiogenic therapy, with higher 18F-RGD uptake in tumors predicting a better response to apatinib therapy.
KeywordsAntiangiogenic therapy Malignancies 18F-RGD PET/CT Integrin αvβ3
The authors would like to thank Ms. Laney Weber for excellent assistance.
This study was partially funded by Shandong Key Research and Development Plan (2017CXGC1209 and 2017GSF18164) and the Outstanding Youth Natural Science Foundation of Shandong Province (JQ201423), Jinan Clinical Medicine Science and Technology Innovation Plan (201704095), NSFC81372413, National Key Research and Development Program of China (2016YFC0904700).
Compliance with ethical standards
Conflict of interest
The authors declare no potential conflicts of interest.
Our investigation was approved by the Shandong Cancer Hospital affiliated to Shandong University Ethical Committee. All persons gave their informed consent prior to their inclusion in the study.
- 1.Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3:65–71.Google Scholar
- 4.Abdelrahim M, Konduri S, Basha R, Philip PA, Baker CH. Angiogenesis: an update and potential drug approaches (review). Int J Oncol. 2010;36:5–18.Google Scholar
- 5.U.S. National Library of Medicine (2009–2012) Efficacy study of [F-18]RGD-K5 positron emission tomography (PET) as a tool to monitor response to an anti-angiogenic drug. ClinicalTrials.gov Identifier: NCT00988936. Sponsor: Siemens Molecular ImagingGoogle Scholar
- 6.Winick J (2007 A proof-of-concept study to assess the ability of [18F]AH- 111585 PET imaging to detect tumours and angiogenesis. ClinicalTrials.gov; November 28, 2007 ed. US: National Institutes of Health; 2007.Google Scholar
- 12.Beer AJ, Haubner R, Wolf I, Goebel M, Luderschmidt S, Niemeyer M, et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med. 2006;47:763–9.Google Scholar
- 16.Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2014;2:123.Google Scholar
- 22.Ji S, Zheng Y, Shao G, Zhou Y, Liu S. Integrin alpha(v)beta(3)-targeted radiotracer (99m)Tc-3P-RGD(2) useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin alpha(v)beta(3) RGD(2) therapy. Theranostics. 2013;3:816–30.CrossRefGoogle Scholar